Role of 2-methoxyestradiol, an endogenous estrogen metabolite, in health and disease

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 5, 2015, Pages 427-438

  Parada Bustamante, Alexis ^a   Valencia, Cecilia ^a   Reuquén, Patricia ^b,c   Díaz, Patricia ^b,c   Rincón Rodriguez, Ramiro ^c,d   Orihuela, Pedro A ^b,c  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^c CENTER FOR THE DEVELOPMENT OF NANOSCIENCE AND NANOTECHNOLOGY CEDENNA   (Chile)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

2 methoxyestradiol; Biomarkers; Estradiol; Estrogen receptor; Gene expression

Indexed keywords

2 METHOXYESTRADIOL; ESTROGEN; REACTIVE OXYGEN METABOLITE; 2-METHOXYESTRADIOL; CATECHOL METHYLTRANSFERASE; DRUG CARRIER; ESTRADIOL; ESTROGEN RECEPTOR;

ARTICLE; BRAIN DAMAGE; CELL DEATH; CLINICAL TRIAL (TOPIC); ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HYDROXYLATION; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SMOOTH MUSCLE CONTRACTION; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MICROTUBULE; NEOPLASMS; REPRODUCTION;

ANIMALS; APOPTOSIS; CATECHOL O-METHYLTRANSFERASE; DRUG CARRIERS; ESTRADIOL; HUMANS; MICROTUBULES; NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; REPRODUCTION;

EID: 84928950036     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150226121052     Document Type: Article

References (161)

1. Carreau, S.; Bouraima-Lelong, H.; Delalande, C. Estrogens: new players in spermatogenesis. Reprod Biol., 2011, 11(3), 174-193.
2. Drummond, A.E.; Fuller, P.J. Ovarian actions of estrogen receptorbeta: an update. Semin Reprod Med., 2012, 30(1), 32-38.
3. Groothuis, P.G.; Dassen, H.H.; Romano, A.; Punyadeera, C. Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human. Hum. Reprod. Update, 2007, 13(4), 405-417.
4. Khosla, S.; Oursler, M.J.; Monroe, D.G. Estrogen and the skeleton. Trends Endocrinol Metab., 2012, 23(11), 576-581.
5. Brown, C.M.; Suzuki, S.; Jelks, K.A.; Wise, P.M. Estradiol is a potent protective, restorative, and trophic factor after brain injury. Semin Reprod Med., 2009, 27(3), 240-249.
6. Leung, S.W.; Teoh, H.; Keung, W.; Man, R.Y. Non-genomic vascular actions of female sex hormones: physiological implications and signalling pathways. Clin. Exp. Pharmacol. Physiol., 2007, 34(8), 822-826.
7. Cheskis, B.J.; Greger, J.G.; Nagpal, S.; Freedman, L.P. Signaling by estrogens. J. Cell Physiol., 2007, 213(3), 610-617.
8. Coleman, K.M.; Smith, C.L. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci., 2001, 1(6), D1379-1391.
9. Orihuela, P.A.; Parada-Bustamante, A.; Zuniga, L.M.; Croxatto, H.B. Inositol triphosphate participates in an oestradiol nongenomic signalling pathway involved in accelerated oviductal transport in cycling rats. J. Endocrinol., 2006, 188(3), 579-588.
10. Tsuchiya, Y.; Nakajima, M.; Yokoi, T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett, 2005, 227(2), 115-124.
11. Parada-Bustamante, A.; Orihuela, P.A.; Rios, M.; Navarrete-Gomez, P.A.; Cuevas, C.A.; Velasquez, L.A.; Villalon, M.J.; Croxatto, H.B. Catechol-o-methyltransferase and methoxyestradiols participate in the intraoviductal nongenomic pathway through which estradiol accelerates egg transport in cycling rats. Biol. Reprod., 2007, 77(6), 934-941.
12. Zhu, B.T.; Conney, A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis, 1998, 19(1), 1-27.
13. Pinto, M.P.; Medina, R.A.; Owen, G.I. 2-methoxyestradiol and disorders of female reproductive tissues. Horm Cancer, 2014, 5(5), 274-283.
14. Parada-Bustamante, A.; Orihuela, P.A.; Molina, C.; Cardenas, H.; Reuquen, P.; Valencia, C.; Rincon, R. In: Estradiol: synthesis, health effects and drug interactions. R. Palmieri; S. Grimaudo, Ed. Nova Science Publishers: New York, 2013; Vol 1, pp. 121-142.
15. Vihko, P.; Isomaa, V.; Ghosh, D. Structure and function of 17betahydroxysteroid dehydrogenase type 1 and type 2. Mol. Cell Endocrinol., 2001, 171(1-2), 71-76.
16. Kohen, P.; Henriquez, S.; Rojas, C.; Gerk, P.M.; Palomino, W.A.; Strauss, J.F., 3rd; Devoto, L. 2-Methoxyestradiol in the human corpus luteum throughout the luteal phase and its influence on lutein cell steroidogenesis and angiogenic activity. Fertil Steril., 2013, 100(5), 1397-1404.
17. Hevir, N.; Ribic-Pucelj, M.; Lanisnik Rizner, T. Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: a source of excessive hydroxy-estrogens and ROS? Mol. Cell Endocrinol., 2013, 367(1-2), 74-84.
18. DuBois, B.N.; O'Tierney-Ginn, P.; Pearson, J.; Friedman, J.E.; Thornburg, K.; Cherala, G. Maternal obesity alters feto-placental cytochrome P4501A1 activity. Placenta, 2012, 33(12), 1045-1051.
19. Kanasaki, K.; Palmsten, K.; Sugimoto, H.; Ahmad, S.; Hamano, Y.; Xie, L.; Parry, S.; Augustin, H.G.; Gattone, V.H.; Folkman, J.; Strauss, J.F.; Kalluri, R. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature, 2008, 453(7198), 1117-1121.
20. John, K.; Ragavan, N.; Pratt, M.M.; Singh, P.B.; Al-Buheissi, S.; Matanhelia, S.S.; Phillips, D.H.; Poirier, M.C.; Martin, F.L. Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate. Prostate, 2009, 69(5), 505-519.
21. Vargas, C. Expression of the enzymes CYP1A1, CYP1B1 and COMT in human testicular tissue. Bs Thesis, Metropolitan Technological University of Chile (UTEM) and University of Chile, June 2013.
22. Lee, A.J.; Cai, M.X.; Thomas, P.E.; Conney, A.H.; Zhu, B.T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology, 2003, 144(8), 3382-3398.
23. Bock, K.W. Homeostatic control of xeno-and endobiotics in the drug-metabolizing enzyme system. Biochem. Pharmacol., 2014, 90(1), 1-6.
24. Badal, S.; Delgoda, R. Role of the modulation of CYP1A1 expression and activity in chemoprevention. J. Appl. Toxicol., 2014, 34(7), 743-753.
25. Androutsopoulos, V.P.; Tsatsakis, A.M.; Spandidos, D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer, 2009, 9, 187.
26. Esakky, P.; Hansen, D.A.; Drury, A.M.; Moley, K.H. Cigarette smoke condensate induces aryl hydrocarbon receptor-dependent changes in gene expression in spermatocytes. Reprod. Toxicol., 2012, 34(4), 665-676.
27. Raza, H.; John, A.; Nemmar, A. Short-term effects of nose-only cigarette smoke exposure on glutathione redox homeostasis, cytochrome P450 1A1/2 and respiratory enzyme activities in mice tissues. Cell Physiol. Biochem., 2013, 31(4-5), 683-692.
28. Mandal, P.K. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J. Comp. Physiol. B., 2005, 175(4), 221-230.
29. Korashy, H.M.; Abuohashish, H.M.; Maayah, Z.H. The role of aryl hydrocarbon receptor-regulated cytochrome P450 enzymes in glioma. Curr. Pharm. Des., 2013, 19(40), 7155-7166.
30. Mannisto, P.T.; Kaakkola, S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev., 1999, 51(4), 593-628.
31. Stubelius, A.; Erlandsson, M.C.; Islander, U.; Carlsten, H. Immunomodulation by the estrogen metabolite 2-methoxyestradiol. Clin. Immunol., 2014, 153(1), 40-48.
32. Sutherland, T.E.; Schuliga, M.; Harris, T.; Eckhardt, B.L.; Anderson, R.L.; Quan, L.; Stewart, A.G. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin. Cancer Res., 2005, 11(5), 1722-1732.
33. D'Amato, R.J.; Lin, C.M.; Flynn, E.; Folkman, J.; Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. U.S.A., 1994, 91(9), 3964-3968.
34. Klauber, N.; Parangi, S.; Flynn, E.; Hamel, E.; D'Amato, R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res., 1997, 57(1), 81-86.
35. Pribluda, V.S.; Gubish, E.R., Jr.; Lavallee, T.M.; Treston, A.; Swartz, G.M.; Green, S.J. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev., 2000, 19(1-2), 173-179.
36. Thaver, V.; Lottering, M.L.; van Papendorp, D.; Joubert, A. In vitro effects of 2-methoxyestradiol on cell numbers, morphology, cell cycle progression, and apoptosis induction in oesophageal carcinoma cells. Cell Biochem. Funct., 2009, 27(4), 205-210.
37. Chua, Y.S.; Chua, Y.L.; Hagen, T. Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Mol. Cancer Ther., 2010, 9(1), 224-235.
38. Stander, B.A.; Marais, S.; Vorster, C.J.; Joubert, A.M. In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line. J. Steroid Biochem. Mol. Biol., 2010, 119(3-5), 149-160.
39. Ting, C.M.; Lee, Y.M.; Wong, C.K.; Wong, A.S.; Lung, H.L.; Lung, M.L.; Lo, K.W.; Wong, R.N.; Mak, N.K. 2-Methoxyestradiol induces endoreduplication through the induction of mitochondrial oxidative stress and the activation of MAPK signaling pathways. Biochem. Pharmacol., 2010, 79(6), 825-841.
40. Kato, S.; Sadarangani, A.; Lange, S.; Delpiano, A.M.; Vargas, M.; Branes, J.; Carvajal, J.; Lipkowitz, S.; Owen, G.I.; Cuello, M.A. 2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts. Reprod Sci., 2008, 15(9), 878-894.
41. Zhang, Q.; Ma, Y.; Cheng, Y.F.; Li, W.J.; Zhang, Z.; Chen, S.Y. Involvement of reactive oxygen species in 2-methoxyestradiolinduced apoptosis in human neuroblastoma cells. Cancer Lett., 2011, 313(2), 201-210.
42. Fussell, K.C.; Udasin, R.G.; Smith, P.J.; Gallo, M.A.; Laskin, J.D. Catechol metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen species in breast epithelial cells. Carcinogenesis, 2011, 32(8), 1285-1293.
43. Stubelius, A.; Andreasson, E.; Karlsson, A.; Ohlsson, C.; Tivesten, A.; Islander, U.; Carlsten, H. Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis. Clin Immunol., 2011, 140(1), 37-46.
44. Basini, G.; Santini, S.E.; Grasselli, F. 2-Methoxyestradiol inhibits superoxide anion generation while it enhances superoxide dismutase activity in swine granulosa cells. Ann. N.Y. Acad. Sci., 2006, 34-40.
45. Liu, W.; Shen, S.M.; Zhao, X.Y.; Chen, G.Q. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int. J. Biochem. Mol. Biol., 2012, 3(2), 165-178.
46. Brocato, J.; Chervona, Y.; Costa, M. Molecular responses to hypoxia-inducible factor 1alpha and beyond. Mol. Pharmacol., 2014, 85(5), 651-657.
47. Zhou, H.; Chen, X.; Zhang, W.M.; Zhu, L.P.; Cheng, L. HIF-1 alpha inhibition reduces nasal inflammation in a murine allergic rhinitis model. PLoS One, 2012, 7(11), 1.
48. Mo, J.H.; Kim, J.H.; Lim, D.J.; Kim, E.H. The role of hypoxiainducible factor 1alpha in allergic rhinitis. Am. J. Rhinol. Allergy, 2014, 28(2), e100-106.
49. Shenaq, M.; Kassem, H.; Peng, C.; Schafer, S.; Ding, J.Y.; Fredrickson, V.; Guthikonda, M.; Kreipke, C.W.; Rafols, J.A.; Ding, Y. Neuronal damage and functional deficits are ameliorated by inhibition of aquaporin and HIF1alpha after traumatic brain injury (TBI). J. Neurol. Sci., 2012, 323(1-2), 134-140.
50. Schaible, E.V.; Windschugl, J.; Bobkiewicz, W.; Kaburov, Y.; Dangel, L.; Kramer, T.; Huang, C.; Sebastiani, A.; Luh, C.; Werner, C.; Engelhard, K.; Thal, S.C.; Schafer, M.K. 2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1alpha response after traumatic brain injury in mice. J. Neurochem., 2014, 129(6), 940-954.
51. Lee, S.B.; Wong, A.P.; Kanasaki, K.; Xu, Y.; Shenoy, V.K.; McElrath, T.F.; Whitesides, G.M.; Kalluri, R. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am. J. Pathol., 2010, 176(2), 710-720.
52. Perez-Sepulveda, A.; Espana-Perrot, P.P.; Norwitz, E.R.; Illanes, S.E. Metabolic pathways involved in 2-methoxyestradiol synthesis and their role in preeclampsia. Reprod Sci., 2013, 20(9), 1020-1029.
53. 2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell., 2003, 3(4), 363-375.
54. Carbonaro, M.; O'Brate, A.; Giannakakou, P. Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J. Cell Biol., 2011, 192(1), 83-99.
55. Banerjee, S.; Randeva, H.; Chambers, A.E. Mouse models for preeclampsia: disruption of redox-regulated signaling. Reprod Biol Endocrinol, 2009, 7, 4.
56. Koganti, S.; Snyder, R.; Gumaste, U.; Karamyan, V.T.; Thekkumkara, T. 2-methoxyestradiol binding of GPR30 downregulates angiotensin AT(1) receptor. Eur. J. Pharmacol., 2014, 723, 131-140.
57. Dubey, R.K.; Jackson, E.K.; Keller, P.J.; Imthurn, B.; Rosselli, M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension, 2001, 37(2 Pt 2), 640-644.
58. Barchiesi, F.; Jackson, E.K.; Fingerle, J.; Gillespie, D.G.; Odermatt, B.; Dubey, R.K. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ. Res., 2006, 99(3), 266-274.
59. Chang, I.; Majid, S.; Saini, S.; Zaman, M.S.; Yamamura, S.; Chiyomaru, T.; Shahryari, V.; Fukuhara, S.; Deng, G.; Dahiya, R.; Tanaka, Y. Hrk mediates 2-methoxyestradiol-induced mitochondrial apoptotic signaling in prostate cancer cells. Mol. Cancer Ther., 2013, 12(6), 1049-1059.
60. Lorin, S.; Borges, A.; Ribeiro Dos Santos, L.; Souquere, S.; Pierron, G.; Ryan, K.M.; Codogno, P.; Djavaheri-Mergny, M. c-Jun NH2-terminal kinase activation is essential for DRAMdependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated Ewing sarcoma cells. Cancer Res., 2009, 69(17), 6924-6931.
61. Lorin, S.; Pierron, G.; Ryan, K.M.; Codogno, P.; Djavaheri-Mergny, M. Evidence for the interplay between JNK and p53-DRAM signalling pathways in the regulation of autophagy. Autophagy, 2010, 6(1), 153-154.
62. Lee, Y.M.; Ting, C.M.; Cheng, Y.K.; Fan, T.P.; Wong, R.N.; Lung, M.L.; Mak, N.K. Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells. Cancer Lett., 2008, 268(2), 295-307.
63. Yang, C.; Shogren, K.L.; Goyal, R.; Bravo, D.; Yaszemski, M.J.; Maran, A. RNA-dependent protein kinase is essential for 2-methoxyestradiol-induced autophagy in osteosarcoma cells. PLoS One, 2013, 8(3), 19.
64. Joubert, A.; Marais, S. In vitro effects of 2-methoxyestradiol on cell morphology and Cdc2 kinase activity in SNO oesophageal carcinoma cells. Cell Biochem. Funct., 2007, 25(3), 357-362.
65. Gui, Y.; Zheng, X.L.; Zheng, J.; Walsh, M.P. Inhibition of rat aortic smooth muscle contraction by 2-methoxyestradiol. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(5), H1935-1942.
66. Hill, B.J.; Gebre, S.; Schlicker, B.; Jordan, R.; Necessary, S. Nongenomic inhibition of coronary constriction by 17ss-estradiol, 2-hydroxyestradiol, and 2-methoxyestradiol. Can. J. Physiol. Pharmacol., 2010, 88(2), 147-152.
67. Goyache, F.M.; Gutierrez, M.; Hidalgo, A.; Cantabrana, B. Nongenomic effects of catecholestrogens in the in vitro rat uterine contraction. Gen. Pharmacol., 1995, 26(1), 219-223.
68. Croxatto, H. Gamete transport J.R. EY Adashi, and Z Rosenwaks Z., Lippincott-Raven Publishers: Philadelphia, 1996; 1, pp. 385-402.
69. Sutter, T.R.; Tang, Y.M.; Hayes, C.L.; Wo, Y.Y.; Jabs, E.W.; Li, X.; Yin, H.; Cody, C.W.; Greenlee, W.F. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem., 1994, 269(18), 13092-13099.
70. Shimada, T.; Hayes, C.L.; Yamazaki, H.; Amin, S.; Hecht, S.S.; Guengerich, F.P.; Sutter, T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res., 1996, 56(13), 2979-2984.
71. Nishimura, M.; Yaguti, H.; Yoshitsugu, H.; Naito, S.; Satoh, T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi, 2003, 123(5), 369-375.
72. Leung, G.S.; Kawai, M.; Tai, J.K.; Chen, J.; Bandiera, S.M.; Chang, T.K. Developmental expression and endocrine regulation of CYP1B1 in rat testis. Drug Metab. Dispos., 2009, 37(3), 523-528.
73. Deb, S.; Kawai, M.; Chang, T.K.; Bandiera, S.M. CYP1B1 expression in rat testis and Leydig cells is not inducible by aryl hydrocarbon receptor agonists. Xenobiotica, 2010, 40(7), 447-457.
74. Choudhary, D.; Jansson, I.; Schenkman, J.B.; Sarfarazi, M.; Stoilov, I. Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys., 2003, 414(1), 91-100.
75. Revel, A.; Raanani, H.; Younglai, E.; Xu, J.; Han, R.; Savouret, J.F.; Casper, R.F. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects sperm from DNA damage and apoptosis caused by benzo(a)pyrene. Reprod. Toxicol., 2001, 15(5), 479-486.
76. Overbye, A.; Seglen, P.O. Phosphorylated and non-phosphorylated forms of catechol O-methyltransferase in rat liver, brain and other tissues. Biochem. J., 2009, 417(2), 535-545.
77. Axelrod, L.R.; Goldzieher, J.W. Formation of 2-methoxyestradiol-17beta in human steroid-producing tissues by a transmethylation reaction. Endocrinology, 1962, 70, 943-945.
78. Molina, C. Effects of Hydroxyestradiols and Methoxyestradiols on viability and transcriptional response to testosterone in isolated Sertoli cells. Bs Thesis, Metropolitan Technological University of Chile (UTEM) and University of Chile, March 2013
79. Valencia, C. Effects of Hydroxyestradiols and Methoxyestradiols on viability of isolated Leydig cells. Bs Thesis, University of Frontier of Chile (UFRO) and University of Chile, January 2014
80. Mueck, A.O.; Seeger, H. 2-Methoxyestradiol--biology and mechanism of action. Steroids, 2010, 75(10), 625-631.
81. Bianchi, F.; Careri, M.; Mangia, A.; Musci, M.; Santini, S.E.; Basini, G. Porcine follicular fluids: comparison of solid-phase extraction and matrix solid-phase dispersion for the GC-MS determination of hormones during follicular growth. J. Pharm. Biomed. Anal., 2007, 44(3), 711-717.
82. Salih, S.M.; Salama, S.A.; Fadl, A.A.; Nagamani, M.; Al-Hendy, A. Expression and cyclic variations of catechol-O-methyl transferase in human endometrial stroma. Fertil Steril., 2008, 90(3), 789-797.
83. Parada-Bustamante, A.; Orihuela, P.A.; Rios, M.; Cuevas, C.A.; Orostica, M.L.; Velasquez, L.A.; Villalon, M.J.; Croxatto, H.B. A non-genomic signaling pathway shut down by mating changes the estradiol-induced gene expression profile in the rat oviduct. Reproduction, 2010, 139(3), 631-644.
84. Orostica, M.L.; Lopez, J.; Rojas, I.; Rocco, J.; Diaz, P.; Reuquen, P.; Cardenas, H.; Parada-Bustamante, A.; Orihuela, P.A. Estradiol increases cAMP in the oviductal secretory cells through a nongenomic mechanism. Reproduction, 2014, 148(3), 285-294.
85. Lattanzi, M.L.; Santos, C.B.; Mudry, M.D.; Baranao, J.L. Exposure of bovine oocytes to the endogenous metabolite 2-methoxyestradiol during in vitro maturation inhibits early embryonic development. Biol. Reprod., 2003, 69(6), 1793-1800.
86. Rincon-Rodriguez, R.J.; Orostica, M.L.; Diaz, P.; Reuquen, P.; Cardenas, H.; Orihuela, P.A. Changes in the gene expression pattern induced by 2-methoxyestradiol in the mouse uterus. Endocrine, 2013, 44(3), 773-783.
87. Martucci, C.P.; Fishman, J. Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology, 1979, 105(6), 1288-1292.
88. Sibonga, J.D.; Lotinun, S.; Evans, G.L.; Pribluda, V.S.; Green, S.J.; Turner, R.T. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology, 2003, 144(3), 785-792.
89. Davis, C.J.; McMillan, L. Pain in endometriosis: effectiveness of medical and surgical management. Curr. Opin. Obstet. Gynecol., 2003, 15(6), 507-512.
90. Bulun, S.E. Endometriosis. N Engl J Med, 2009, 360(3), 268-279.
91. Singh, M.N.; Stringfellow, H.F.; Taylor, S.E.; Ashton, K.M.; Ahmad, M.; Abdo, K.R.; El-Agnaf, O.M.; Martin-Hirsch, P.L.; Martin, F.L. Elevated expression of CYP1A1 and gamma-SYNUCLEIN in human ectopic (ovarian) endometriosis compared with eutopic endometrium. Mol. Hum. Reprod., 2008, 14(11), 655-663.
92. Becker, C.M.; Rohwer, N.; Funakoshi, T.; Cramer, T.; Bernhardt, W.; Birsner, A.; Folkman, J.; D'Amato, R.J. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am. J. Pathol., 2008, 172(2), 534-544.
93. Sibai, B.; Dekker, G.; Kupferminc, M. Pre-eclampsia. Lancet, 2005, 365(9461), 785-799.
94. Chesley, L.C. Hypertensive disorders in pregnancy. J. Nurse Midwifery, 1985, 30(2), 99-104.
95. Roberts, J.M.; Taylor, R.N.; Musci, T.J.; Rodgers, G.M.; Hubel, C.A.; McLaughlin, M.K. Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol., 1989, 161(5), 1200-1204.
96. Dragun, D.; Haase-Fielitz, A. Low catechol-O-methyltransferase and 2-methoxyestradiol in preeclampsia: more than a unifying hypothesis. Nephrol. Dial. Transplant, 2009, 24(1), 31-33.
97. Shenoy, V.; Kanasaki, K.; Kalluri, R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab., 2010, 21(9), 529-536.
98. Jobe, S.O.; Ramadoss, J.; Wargin, A.J.; Magness, R.R. Estradiol-17beta and its cytochrome P450-and catechol-O-methyltransferasederived metabolites selectively stimulate production of prostacyclin in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta. Hypertension, 2013, 61(2), 509-518.
99. Lim, J.H.; Kim, S.Y.; Kim do, J.; Park, S.Y.; Han, H.W.; Han, J.Y.; Lee, S.W.; Yang, J.H.; Ryu, H.M. Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17alpha in preeclampsia. Pharmacogenet Genomics, 2010, 20(10), 605-610.
100. Liang, S.; Liu, X.; Fan, P.; Liu, R.; Zhang, J.; He, G.; Liu, Y.; Bai, H. Association between Val158Met functional polymorphism in the COMT gene and risk of preeclampsia in a Chinese population. Arch. Med. Res., 2012, 43(2), 154-158.
101. Caniggia, I.; Mostachfi, H.; Winter, J.; Gassmann, M.; Lye, S.J.; Kuliszewski, M.; Post, M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J. Clin. Invest., 2000, 105(5), 577-587.
102. Tal, R.; Shaish, A.; Barshack, I.; Polak-Charcon, S.; Afek, A.; Volkov, A.; Feldman, B.; Avivi, C.; Harats, D. Effects of hypoxiainducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. Am. J. Pathol., 2010, 177(6), 2950-2962.
103. Nishi, H.; Nakada, T.; Kyo, S.; Inoue, M.; Shay, J.W.; Isaka, K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell Biol., 2004, 24(13), 6076-6083.
104. Vuorela, P.; Helske, S.; Hornig, C.; Alitalo, K.; Weich, H.; Halmesmaki, E. Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet. Gynecol., 2000, 95(3), 353-357.
105. Sood, R.; Faubion, S.S.; Kuhle, C.L.; Thielen, J.M.; Shuster, L.T. Prescribing menopausal hormone therapy: an evidence-based approach. Int. J. Womens Health, 2014, 6, 47-57.
106. Resanovic, I.; Rizzo, M.; Zafirovic, S.; Bjelogrlic, P.; Perovic, M.; Savic, K.; Patti, A.M.; Isenovic, R.E. Anti-atherogenic effects of 17beta-estradiol. Horm Metab. Res., 2013, 45(10), 701-708.
107. Karas, R.H.; Hodgin, J.B.; Kwoun, M.; Krege, J.H.; Aronovitz, M.; Mackey, W.; Gustafsson, J.A.; Korach, K.S.; Smithies, O.; Mendelsohn, M.E. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc. Natl. Acad Sci. U.S.A., 1999, 96(26), 15133-15136.
108. Koganti, S.; Snyder, R.; Thekkumkara, T. Pharmacologic effects of 2-methoxyestradiol on angiotensin type 1 receptor down-regulation in rat liver epithelial and aortic smooth muscle cells. Gend. Med., 2012, 9(2), 76-93.
109. Semenza, G.L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell, 2001, 107(1), 1-3.
110. Chang, Y.; Hsiao, G.; Chen, S.H.; Chen, Y.C.; Lin, J.H.; Lin, K.H.; Chou, D.S.; Sheu, J.R. Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacol. Sin., 2007, 28(3), 327-333.
111. Chen, W.; Jadhav, V.; Tang, J.; Zhang, J.H. HIF-1alpha inhibition ameliorates neonatal brain injury in a rat pup hypoxic-ischemic model. Neurobiol. Dis., 2008, 31(3), 433-441.
112. Mooberry, S.L. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist. Updat, 2003, 6(6), 355-361.
113. Matsumoto, C.; Shinkai, T.; Hori, H.; Ohmori, O.; Nakamura, J. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res., 2004, 127(1-2), 1-7.
114. Abdolmaleky, H.M.; Cheng, K.H.; Faraone, S.V.; Wilcox, M.; Glatt, S.J.; Gao, F.; Smith, C.L.; Shafa, R.; Aeali, B.; Carnevale, J.; Pan, H.; Papageorgis, P.; Ponte, J.F.; Sivaraman, V.; Tsuang, M.T.; Thiagalingam, S. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet, 2006, 15(21), 3132-3145.
115. Xiao, S.; Gillespie, D.G.; Baylis, C.; Jackson, E.K.; Dubey, R.K. Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. Hypertension, 2001, 37(2 Pt 2), 645-650.
116. Tofovic, P.S.; Rosado, B.M.; Dubey, K.R.; Mi, Z.; Jackson, E.K. Effects of estradiol metabolites on cAMP production and degradation. Prilozi, 2009, 30(1), 5-24.
117. Schumacher, G.; Kataoka, M.; Roth, J.A.; Mukhopadhyay, T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin. Cancer Res., 1999, 5(3), 493-499.
118. Arbiser, J.L.; Panigrathy, D.; Klauber, N.; Rupnick, M.; Flynn, E.; Udagawa, T.; D'Amato, R.J. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J. Am. Acad. Dermatol., 1999, 40(6 Pt 1), 925-929.
119. Dubey, R.K.; Gillespie, D.G.; Keller, P.J.; Imthurn, B.; Zacharia, L.C.; Jackson, E.K. Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells. Hypertension, 2002, 39(2 Pt 2), 418-424.
120. Fotsis, T.; Zhang, Y.; Pepper, M.S.; Adlercreutz, H.; Montesano, R.; Nawroth, P.P.; Schweigerer, L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature, 1994, 368(6468), 237-239.
121. LaVallee, T.M.; Zhan, X.H.; Johnson, M.S.; Herbstritt, C.J.; Swartz, G.; Williams, M.S.; Hembrough, W.A.; Green, S.J.; Pribluda, V.S. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res., 2003, 63(2), 468-475.
122. Lambert, C.; Apel, K.; Biesalski, H.K.; Frank, J. 2-methoxyestradiol induces caspase-independent, mitochondriacentered apoptosis in DS-sarcoma cells. Int. J. Cancer, 2004, 108(4), 493-501.
123. Feng, Y.; Zhao, X.; Zhou, C.; Yang, L.; Liu, Y.; Bian, C.; Gou, J.; Lin, X.; Wang, Z. The associations between the Val158Met in the catechol-O-methyltransferase (COMT) gene and the risk of uterine leiomyoma (ULM). Gene, 2013, 529(2), 296-299.
124. Lin, G.; Zhao, J.; Wu, J.; Andreevich, O.R.; Zhang, W.H.; Zhang, Y.; Yu, L. Contribution of catechol-O-methyltransferase Val158Met polymorphism to endometrial cancer risk in postmenopausal women: a meta-analysis. Genet Mol. Res., 2013, 12(4), 6442-6453.
125. Cho, J.K.; Hong, K.Y.; Park, J.W.; Yang, H.K.; Song, S.C. Injectable delivery system of 2-methoxyestradiol for breast cancer therapy using biodegradable thermosensitive poly(organophosphazene) hydrogel. J. Drug Target, 2011, 19(4), 270-280.
126. Verenich, S.; Gerk, P.M. Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol. Pharm., 2010, 7(6), 2030-2039.
127. Dahut, W.L.; Lakhani, N.J.; Gulley, J.L.; Arlen, P.M.; Kohn, E.C.; Kotz, H.; McNally, D.; Parr, A.; Nguyen, D.; Yang, S.X.; Steinberg, S.M.; Venitz, J.; Sparreboom, A.; Figg, W.D. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther., 2006, 5(1), 22-27.
128. Kambhampati, S.; Rajewski, R.A.; Tanol, M.; Haque, I.; Das, A.; Banerjee, S.; Jha, S.; Burns, D.; Borrego-Diaz, E.; Van Veldhuizen, P.J.; Banerjee, S.K. A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. Mol. Cancer Ther., 2013, 12(3), 255-263.
129. Guo, X.H.; Zhang, N.; Cui, F.D.; Du, B.; Zhang, Z.Z. An investigation on intestinal absorption of a new anticancer drug, 2-methoxyestradiol. Pharmazie, 2009, 64(11), 748-751.
130. Lakhani, N.J.; Sparreboom, A.; Xu, X.; Veenstra, T.D.; Venitz, J.; Dahut, W.L.; Figg, W.D. Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol. J. Pharm. Sci., 2007, 96(7), 1821-1831.
131. Sweeney, C.; Liu, G.; Yiannoutsos, C.; Kolesar, J.; Horvath, D.; Staab, M.J.; Fife, K.; Armstrong, V.; Treston, A.; Sidor, C.; Wilding, G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormonerefractory prostate cancer. Clin. Cancer Res., 2005, 11(18), 6625-6633.
132. Matei, D.; Schilder, J.; Sutton, G.; Perkins, S.; Breen, T.; Quon, C.; Sidor, C. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol. Oncol., 2009, 115(1), 90-96.
133. James, J.; Murry, D.J.; Treston, A.M.; Storniolo, A.M.; Sledge, G.W.; Sidor, C.; Miller, K.D. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest. New Drugs, 2007, 25(1), 41-48.
134. Tevaarwerk, A.J.; Holen, K.D.; Alberti, D.B.; Sidor, C.; Arnott, J.; Quon, C.; Wilding, G.; Liu, G. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res., 2009, 15(4), 1460-1465.
135. 2) NanoCrystal(R) dispersion (NCD) in patients with taxanerefractory, metastatic castrate-resistant prostate cancer (CRPC). Invest. New Drugs, 2011, 29(6), 1465-1474.
136. Newman, S.P.; Ireson, C.R.; Tutill, H.J.; Day, J.M.; Parsons, M.F.; Leese, M.P.; Potter, B.V.; Reed, M.J.; Purohit, A. The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res., 2006, 66(1), 324-330.
137. Liu, Z.J.; Lee, W.J.; Zhu, B.T. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause. Cancer Res., 2005, 65(13), 5802-5811.
138. Sano, T.; Hirasawa, G.; Takeyama, J.; Darnel, A.D.; Suzuki, T.; Moriya, T.; Kato, K.; Sekine, H.; Ohara, S.; Shimosegawa, T.; Nakamura, J.; Yoshihama, M.; Harada, N.; Sasano, H. 17 beta-Hydroxysteroid dehydrogenase type 2 expression and enzyme activity in the human gastrointestinal tract. Clin. Sci. (Lond), 2001, 101(5), 485-491.
139. Du, B.; Li, X.T.; Zhao, Y.; Zhang, Z.Z. Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders. Pharmazie, 2010, 65(7), 471-476.
140. Gutierrez, M.; Escudey, M.; Escrig, J.; Denardin, J.C.; Altbir, D.; Fabris, J.D.; Cavalcante, L.C.D.; Garcia-Gonzalez, M.T. Preparation and Characterization of Magnetic Composites Based on a Natural Zeolite. Clays and Clay Minerals, 2010, 58(5), 589-595.
141. Stubelius, A.; Wilhelmson, A.S.; Gogos, J.A.; Tivesten, A.; Islander, U.; Carlsten, H. Sexual dimorphisms in the immune system of catechol-O-methyltransferase knockout mice. Immunobiology, 2012, 217(8), 751-760.
142. Bruce, J.Y.; Eickhoff, J.; Pili, R.; Logan, T.; Carducci, M.; Arnott, J.; Treston, A.; Wilding, G.; Liu, G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest. New Drugs, 2012, 30(2), 794-802.
143. Kulke, M.H.; Chan, J.A.; Meyerhardt, J.A.; Zhu, A.X.; Abrams, T.A.; Blaszkowsky, L.S.; Regan, E.; Sidor, C.; Fuchs, C.S. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol., 2011, 68(2), 293-300.
144. LaVallee, T.M.; Burke, P.A.; Swartz, G.M.; Hamel, E.; Agoston, G.E.; Shah, J.; Suwandi, L.; Hanson, A.D.; Fogler, W.E.; Sidor, C.F.; Treston, A.M. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol. Cancer Ther., 2008, 7(6), 1472-1482.
145. Moser, C.; Lang, S.A.; Mori, A.; Hellerbrand, C.; Schlitt, H.J.; Geissler, E.K.; Fogler, W.E.; Stoeltzing, O. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer, 2008, 8, 206.
146. Snoeks, T.J.; Mol, I.M.; Que, I.; Kaijzel, E.L.; Lowik, C.W. 2-methoxyestradiol analogue ENMD-1198 reduces breast cancerinduced osteolysis and tumor burden both in vitro and in vivo. Mol. Cancer Ther., 2011, 10(5), 874-882.
147. Zhou, Q.; Gustafson, D.; Nallapareddy, S.; Diab, S.; Leong, S.; Lewis, K.; Gore, L.; Messersmith, W.A.; Treston, A.M.; Eckhardt, S.G.; Sidor, C.; Camidge, D.R. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs, 2011, 29(2), 340-346.
148. Suzuki, R.N.; Newman, S.P.; Purohit, A.; Leese, M.P.; Potter, B.V.; Reed, M.J. Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol., 2003, 84(2-3), 269-278.
149. Raobaikady, B.; Purohit, A.; Chander, S.K.; Woo, L.W.; Leese, M.P.; Potter, B.V.; Reed, M.J. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol., 2003, 84(2-3), 351-358.
150. Ireson, C.R.; Chander, S.K.; Purohit, A.; Perera, S.; Newman, S.P.; Parish, D.; Leese, M.P.; Smith, A.C.; Potter, B.V.; Reed, M.J. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br. J. Cancer, 2004, 90(4), 932-937.
151. Utsumi, T.; Leese, M.P.; Chander, S.K.; Gaukroger, K.; Purohit, A.; Newman, S.P.; Potter, B.V.; Reed, M.J. The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J. Steroid Biochem. Mol. Biol., 2005, 94(1-3), 219-227.
152. Visagie, M.H.; Joubert, A.M. In vitro effects of 2-methoxyestradiol-bis-sulphamate on reactive oxygen species and possible apoptosis induction in a breast adenocarcinoma cell line. Cancer Cell Int., 2011, 11(1), 43.
153. Vorster, C.; Joubert, A. In vitro effects of 2-methoxyestradiol-bissulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line. Biocell, 2010, 34(2), 71-79.
154. Visagie, M.H.; Joubert, A.M. 2-Methoxyestradiol-bis-sulphamate refrains from inducing apoptosis and autophagy in a nontumorigenic breast cell line. Cancer Cell Int., 2012, 12(1), 37.
155. Meyer-Losic, F.; Newman, S.P.; Day, J.M.; Reed, M.J.; Kasprzyk, P.G.; Purohit, A.; Foster, P.A. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/tantigen transgenic mice. PLoS One, 2013, 8(12), e80305.
156. Edsall, A.B.; Agoston, G.E.; Treston, A.M.; Plum, S.M.; McClanahan, R.H.; Lu, T.S.; Song, W.; Cushman, M. Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate. J. Med. Chem., 2007, 50(26), 6700-6705.
157. 2) in multiple myeloma cells using oligonucleotide arrays. Blood, 2003, 101(9), 3606-3614.
158. Barchiesi, F.; Lucchinetti, E.; Zaugg, M.; Ogunshola, O.O.; Wright, M.; Meyer, M.; Rosselli, M.; Schaufelberger, S.; Gillespie, D.G.; Jackson, E.K.; Dubey, R.K. Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. Hypertension, 2010, 56(5), 964-972.
159. Miyazaki, M.; Gomez, F.E.; Ntambi, J.M. Lack of stearoyl-CoA desaturase-1 function induces a palmitoyl-CoA Delta6 desaturase and represses the stearoyl-CoA desaturase-3 gene in the preputial glands of the mouse. J. Lipid Res., 2002, 43(12), 2146-2154.
160. Parks, W.T.; Frank, D.B.; Huff, C.; Renfrew Haft, C.; Martin, J.; Meng, X.; de Caestecker, M.P.; McNally, J.G.; Reddi, A.; Taylor, S.I.; Roberts, A.B.; Wang, T.; Lechleider, R.J. Sorting nexin 6, a novel SNX, interacts with the transforming growth factor-beta family of receptor serine-threonine kinases. J. Biol. Chem., 2001, 276(22), 19332-19339.
161. Hoe, H.S.; Wessner, D.; Beffert, U.; Becker, A.G.; Matsuoka, Y.; Rebeck, G.W. F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol. Cell Biol., 2005, 25(21), 9259-9268.